Charles Schwab Investment Management Inc Madrigal Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $429 Billion
  • Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 122,692 shares of MDGL stock, worth $35.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
122,692
Previous 120,212 2.06%
Holding current value
$35.9 Million
Previous $27.8 Million 17.79%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
BUY
$171.37 - $283.23 $424,997 - $702,410
2,480 Added 2.06%
122,692 $32.8 Million
Q4 2023

Feb 06, 2024
BUY
$120.4 - $237.13 $1.29 Million - $2.54 Million
10,711 Added 9.78%
120,212 $27.8 Million
Q3 2023

Nov 08, 2023
BUY
$146.04 - $225.78 $1.62 Million - $2.5 Million
11,083 Added 11.26%
109,501 $16 Million
Q2 2023

Aug 09, 2023
BUY
$203.88 - $312.0 $1.39 Million - $2.12 Million
6,796 Added 7.42%
98,418 $22.7 Million
Q1 2023

May 11, 2023
BUY
$231.06 - $307.08 $39,742 - $52,817
172 Added 0.19%
91,622 $22.2 Million
Q4 2022

Feb 13, 2023
BUY
$58.39 - $296.54 $115,086 - $584,480
1,971 Added 2.2%
91,450 $26.5 Million
Q3 2022

Nov 14, 2022
BUY
$60.57 - $79.51 $74,440 - $97,717
1,229 Added 1.39%
89,479 $5.82 Million
Q2 2022

Aug 15, 2022
SELL
$58.04 - $100.2 $13,000 - $22,444
-224 Reduced 0.25%
88,250 $6.32 Million
Q1 2022

May 13, 2022
BUY
$55.89 - $101.89 $98,142 - $178,918
1,756 Added 2.02%
88,474 $8.68 Million
Q4 2021

Feb 11, 2022
BUY
$72.34 - $95.09 $278,509 - $366,096
3,850 Added 4.65%
86,718 $7.35 Million
Q3 2021

Nov 16, 2021
BUY
$78.35 - $105.02 $829,413 - $1.11 Million
10,586 Added 14.65%
82,868 $6.61 Million
Q2 2021

Aug 16, 2021
BUY
$97.2 - $137.59 $770,115 - $1.09 Million
7,923 Added 12.31%
72,282 $7.04 Million
Q1 2021

May 17, 2021
BUY
$108.54 - $125.2 $452,720 - $522,209
4,171 Added 6.93%
64,359 $7.53 Million
Q4 2020

Feb 16, 2021
BUY
$110.06 - $133.7 $96,082 - $116,720
873 Added 1.47%
60,188 $6.69 Million
Q3 2020

Nov 13, 2020
SELL
$99.78 - $124.21 $230,192 - $286,552
-2,307 Reduced 3.74%
59,315 $7.04 Million
Q2 2020

Aug 14, 2020
BUY
$60.13 - $125.71 $203,359 - $425,151
3,382 Added 5.81%
61,622 $6.98 Million
Q1 2020

May 15, 2020
BUY
$66.76 - $93.49 $229,053 - $320,764
3,431 Added 6.26%
58,240 $3.89 Million
Q4 2019

Feb 07, 2020
BUY
$84.28 - $118.5 $545,881 - $767,524
6,477 Added 13.4%
54,809 $4.99 Million
Q3 2019

Nov 08, 2019
BUY
$84.4 - $106.53 $85,666 - $108,127
1,015 Added 2.15%
48,332 $4.17 Million
Q2 2019

Aug 09, 2019
BUY
$91.13 - $142.5 $221,172 - $345,847
2,427 Added 5.41%
47,317 $4.96 Million
Q1 2019

May 14, 2019
BUY
$103.48 - $143.84 $264,184 - $367,223
2,553 Added 6.03%
44,890 $5.62 Million
Q4 2018

Feb 14, 2019
SELL
$94.77 - $215.54 $56,956 - $129,539
-601 Reduced 1.4%
42,337 $4.77 Million
Q3 2018

Nov 13, 2018
BUY
$207.3 - $300.31 $6.14 Million - $8.89 Million
29,618 Added 222.36%
42,938 $9.2 Million
Q2 2018

Aug 08, 2018
BUY
$101.55 - $313.9 $344,457 - $1.06 Million
3,392 Added 34.17%
13,320 $3.73 Million
Q1 2018

May 07, 2018
BUY
$93.35 - $149.04 $102,685 - $163,944
1,100 Added 12.46%
9,928 $1.16 Million
Q4 2017

Jan 17, 2018
SELL
$39.35 - $97.37 $195,648 - $484,123
-4,972 Reduced 36.03%
8,828 $811,000
Q3 2017

Nov 13, 2017
BUY
$15.48 - $46.19 $213,624 - $637,422
13,800
13,800 $621,000

Others Institutions Holding MDGL

# of Institutions
314
Shares Held
20M
Call Options Held
824K
Put Options Held
1.04M
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.01B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email